Other interesting presentations from the GU Oncology meeting: Part ...

Posted on February 5, 2012 by Sitemaster

The following is promised commentary on a second group of the more interesting?presentations last Thursday at the Genitourinary Cancer Symposium in San Francisco, with links to the more detailed abstracts. The majority of these presentations were posters as opposed to oral presentations.

• Lin et al. presented data suggesting that, for men initially placed on active surveillance,?PCA3 and TMRPSS2-ERG levels?may be helpful in the?assessment of?risk for aggressive forms of prostate cancer (as defined by tumor volume or Gleason score) and may also have clinical utility in the selection of?men?who are appropriate candidates?for active surveillance.

• Orsted et al. offered additional?insights from a large Danish database on the association between baseline PSA levels and 10-year risk for prostate cancer.

• Parker et al. gave a detailed report on the results of the randomized, muticenter, Phase III clinical trial of radium-223 choride (Alpharadin^?) in the treatment of men with metastatic, castration-resistant prostate cancer.

• Hussain et al. provided initial data from a randomized Phase II trial of cixutumumab or ramucirumab (two monoclonal antibodies) plus mitoxantrone and prednisone in men with mCRPC who had progressive disease on docetaxel-based chemotherapy.

• Small et al. demonstrated that a significant subset of men diagnosed with metastatic prostate cancer still receives no effective treatment, and that such patients tend to be disadvantaged in some way be race, income, and/or educational status.

• Karzai et al. reported on a Phase I trial of an antibody to CD105 (endoglin) and showed that some patients with progressive mCRPC appear to respond to treatment with this antibody.

• Similarly, Chi et al. reported data from a randomized, Phase II trial of OGX-427 suggesting that some men with progressive CRPC seem to respond to treatment with OGX-427 plus prednisone.

• Aizer et al. reported on recent frequency of management of men with low-risk prostate cancer using active surveillance at the multi-disciplinary prostate cancer clinics of three, associated teaching hospitals in Boston, MA.

• Trock et al. offered data on the impact of factors such as diet, supplements, and lifestyle on risk of disease progression in a current, contemporary seriescohort of patients managed with active surveillance.

• An interesting poster by Hattangadi et al. indicates the continued importance of the digital rectal examionation (DRE) in identification of men with high-risk but localized and potentially curable?prostate cancer who have an occult (i.e., non-suspicious) PSA level.

• Ansari et al. reported data on the outcomes of 105 men diagnosed with low- and intermediate-risk prostate cancer and managed with active surveillance at two institutions in Scotland.

Like this:

Be the first to like this post.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment

Source: http://prostatecancerinfolink.net/2012/02/05/other-interesting-presentations-from-the-gu-oncology-meeting-part-ii/

conrad murray verdict tappan zee bridge jessica chastain jessica chastain nook tablet eagles magic johnson